95 related articles for article (PubMed ID: 17325478)
1. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma.
Lin F; Zhang PL; Yang XJ; Shi J; Blasick T; Han WK; Wang HL; Shen SS; Teh BT; Bonventre JV
Am J Surg Pathol; 2007 Mar; 31(3):371-81. PubMed ID: 17325478
[TBL] [Abstract][Full Text] [Related]
2. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K; Onder E
Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive proteogenomic characterization of rare kidney tumors.
Li GX; Chen L; Hsiao Y; Mannan R; Zhang Y; Luo J; Petralia F; Cho H; Hosseini N; Leprevost FDV; Calinawan A; Li Y; Anand S; Dagar A; Geffen Y; Kumar-Sinha C; Chugh S; Le A; Ponce S; Guo S; Zhang C; Schnaubelt M; Al Deen NN; Chen F; Caravan W; Houston A; Hopkins A; Newton CJ; Wang X; Polasky DA; Haynes S; Yu F; Jing X; Chen S; Robles AI; Mesri M; Thiagarajan M; An E; Getz GA; Linehan WM; Hostetter G; Jewell SD; Chan DW; Wang P; Omenn GS; Mehra R; Ricketts CJ; Ding L; Chinnaiyan AM; Cieslik MP; Dhanasekaran SM; Zhang H; Nesvizhskii AI;
Cell Rep Med; 2024 May; 5(5):101547. PubMed ID: 38703764
[TBL] [Abstract][Full Text] [Related]
4. Clear cell renal cell carcinoma cells show diffuse expression of phagocytotic markers through the identification of lysosome-rich eosinophilic granules.
Mahalingam VD; Chaib OS; Kanaan HD; Hafron JM; Zhang PL
Int Urol Nephrol; 2024 Feb; 56(2):467-473. PubMed ID: 37777637
[TBL] [Abstract][Full Text] [Related]
5. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.
Salgia NJ; Zengin ZB; Pal SK; Dizman N
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438642. PubMed ID: 38776514
[TBL] [Abstract][Full Text] [Related]
6. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
Huang RR; Chen Z; Kroeger N; Pantuck A; Said J; Kluger HM; Shuch B; Ye H
Clin Genitourin Cancer; 2024 Apr; 22(2):347-353. PubMed ID: 38195301
[TBL] [Abstract][Full Text] [Related]
7. The impact of the COVID-19 pandemic on renal cancer care.
Yildirim H; Bins AD; van den Hurk C; van Moorselaar RJA; van Oijen MGH; Bex A; Zondervan PJ; Aben KKH
World J Urol; 2024 Apr; 42(1):231. PubMed ID: 38613582
[TBL] [Abstract][Full Text] [Related]
8. Protein expression profiling in the spectrum of renal cell carcinomas.
Valera VA; Li-Ning-T E; Walter BA; Roberts DD; Linehan WM; Merino MJ
J Cancer; 2010 Oct; 1():184-96. PubMed ID: 20975849
[TBL] [Abstract][Full Text] [Related]
9. Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time?
Parikh M
J Kidney Cancer VHL; 2021; 8(4):20-21. PubMed ID: 34722127
[No Abstract] [Full Text] [Related]
10. Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer.
Anić P; Golubić Talić J; Božinović K; Dediol E; Mravak-Stipetić M; Grce M; Milutin Gašperov N
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175405
[TBL] [Abstract][Full Text] [Related]
11. A pan-cancer analysis of HAVCR1 with a focus on diagnostic, prognostic and immunological roles in human cancers.
Li G; Javed M; Rasool R; Abdel-Maksoud MA; Mubarak AS; Studenik CR; Narayanan J; Atuahene SA; Aufy M; Cao K
Am J Transl Res; 2023; 15(3):1590-1606. PubMed ID: 37056808
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.
Mahmoud AM; Nabavizadeh R; Rodrigues Pessoa R; Garg I; Orme J; Costello BA; Cheville J; Lucien F
Oncologist; 2023 Apr; 28(4):297-308. PubMed ID: 36745503
[TBL] [Abstract][Full Text] [Related]
13. The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma.
Berg SA; McGregor BA
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551504
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
[TBL] [Abstract][Full Text] [Related]
15. TIM-1 promotes proliferation and metastasis, and inhibits apoptosis, in cervical cancer through the PI3K/AKT/p53 pathway.
Chen L; Qing J; Xiao Y; Huang X; Chi Y; Chen Z
BMC Cancer; 2022 Apr; 22(1):370. PubMed ID: 35392845
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study.
Chen WJ; Cao H; Cao JW; Zuo L; Qu FJ; Xu D; Zhang H; Gong HY; Chen JX; Ye JQ; Gan SS; Zhou W; Zhu DW; Pan XW; Cui XG
Cell Death Dis; 2022 Jan; 13(1):50. PubMed ID: 35017463
[TBL] [Abstract][Full Text] [Related]
17. Identification of Hypoxia Signature to Assess the Tumor Immune Microenvironment and Predict Prognosis in Patients with Ovarian Cancer.
Wei C; Liu X; Wang Q; Li Q; Xie M
Int J Endocrinol; 2021; 2021():4156187. PubMed ID: 34950205
[TBL] [Abstract][Full Text] [Related]
18. Human kidney injury molecule-1 as a urine biomarker differentiating urothelial and renal cell carcinoma.
Białek Ł; Niemczyk M; Czerwińska K; Nowak M; Sadowska A; Borkowski T; Radziszewski P; Dobruch J; Kryst P; Poletajew S
Cent European J Urol; 2021; 74(3):295-299. PubMed ID: 34729216
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
